switching between glp 1 agonists Capsule 61 - Therapeutic Interchange: from GLP-1 RAs to Dual GLP-1/GIP Receptor | Cardi-OH Capsule | Cardi-OH GLP-1 vs GIP/GLP-1 Agonists: Weekly

This is why gastrointestinal health and food preparation matter

Min SY, Kim HS, Jung EJ, Jung EJ, Jee CD, Kim WH

Closely related in Tesamorelin, which is an FDA approved drug for a narrow indication: patients with HIV lipodystrophy

Cutting funding without considering these downstream cost implications risks shifting expenses rather than eliminating them, potentially creating larger budget impacts over time

Indications and Usage Wegovy (semaglutide) injection is indicated in combination with a reduced calorie diet and increased physical activity: To reduce the risk of major adverse cardiovascular (CV) events (CV death, non-fatal myocardial infarction, or non-fatal stroke) in adults with established CV disease and either obesity or overweight To reduce excess body weight and maintain weight reduction long term in: Adults and pediatric patients 12 years and older with obesity Adults with overweight in the presence of at least one weight-related comorbidity Wegovy (semaglutide) tablets are indicated in combination with a reduced calorie diet and increased physical activity to: Reduce the risk of major adverse cardiovascular (CV) events (CV death, non-fatal myocardial infarction, or non-fatal stroke) in adults with established CV disease and either obesity or overweight Reduce excess body weight and maintain weight reduction long term in adults with obesity or with overweight in the presence of at least one weight-related comorbidity Limitations of Use: Concomitant use of Wegovy tablets or Wegovy injection with other semaglutide-containing products or with any GLP-1 receptor agonist is not recommended References Wegovy [package insert]